• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    PCI Pharma Services

    Adare Pharma Solutions

    Aphena Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Inquiring Minds Want to Know, Just Ask FDA

    What you need to know prior to submission

    Inquiring Minds Want to Know, Just Ask FDA
    Michelle Ryder, Lachman Consultant04.01.20
    How many conversations, or shall we call them “debates”, have you had within your organization trying to decipher exactly what FDA means in a guidance document, presentation, or even in a product specific information request or a Complete Response Letter (CRL)? It’s not always easy to draw out the actual intent of a general statement or infer from a guidance, which applies to a broad category of products, the relevance to your very specific generic product development program.

    To be fair, FDA does its best to continue to update current guidance documents and issue new guidance to address the common questions received from Industry, as well as the common deficiency trends it sees during its application reviews. However, what is one to do when it is not clear? 

    Not completing the appropriate requisite studies to support approval of your program can have dire consequences, including Refuse to Receive (RTR), additional review cycles, all the way to a non-approvability determination. Nobody wants to go there.

    Are you afraid to ask, because you may not like the answer? Or worse, management won’t like the answer? Well, better to know now than hear about it in an RTR or CRL and have earned yourself another review cycle for a product that promises great gains for your company. 

    Don’t despair, for there are a few avenues FDA has opened to get to your destination of knowing what you need to know prior to submission.

    Controlled Correspondence (CC)
    This is a great tool to ask FDA about Q1Q2 assessments, batch size or bracketing strategies, inactive ingredient levels, or even general Post Approval submission requirements, to name a few; and submitting a controlled correspondence has never been easier. The CC is submitted through the NextGen Portal, and FDA has issued Draft Guidance1 that details what types of questions qualify for CC, how to submit, what should be included in your CC, which review discipline you should choose, and how to go about requesting clarification to your response, if necessary. But before we get too excited about just how easy this is, there are some intricacies in the process to be aware of. 

    Let’s consider the simple request of a Q1Q2 evaluation. Xiaohui (Jeff) Jiang, Ph.D., Deputy Director of Division of Therapeutic Performance, OGD, CDER, FDA, gave a very informative presentation at last year’s Generic + Biosimilar Medicines Conference titled Navigating Q1/Q2 for Complex Generics.2 In the presentation, Jeff discussed how a simple Q1Q2 evaluation request may not always be so simple, especially when we are discussing products/routes of administration that are not required to be Q1Q2 for ANDA submission.

    However, if your product has an alternate BE approach listed in its Product Specific Guidance (PSG) you may still be able to get the Q1Q2 evaluation—but the devil is in the details. Rather than requesting a Q1Q2 evaluation of your test formulations in the CC, you will be asking FDA to make a determination of whether or not your formulations are eligible for a particular BE approach. Seems a little nitpicky, but we’ve seen CC refusals based on this. (As a side note, you will still be choosing the Q1Q2 assessment option in the NextGen Portal.)

    Another common mistake is combining multiple questions for multiple review disciplines into one CC.  This will get kicked back every time and you will have to submit separate CCs for each review discipline.

    You will likely see that there is some trial and error in getting CCs accepted.  One thing we can say for sure is that FDA is strict about enforcing the Draft Guidance1 in terms of required elements of the CC, review disciplines, and what is and is not acceptable as a CC. 

    Meetings with FDA
    No longer just a tool for NDAs, GDUFA has given industry the gift of formal meetings with FDA for Complex Products. The logistics of this process are not the same for ANDAs as they are for NDAs, so be sure to reference FDA’s Draft Guidance: Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA.3 ANDA sponsors have multiple opportunities here, and before you shy away because you don’t think your product is “complex” enough, make note that within the guidance, reference is made to the GDUFA II Commitment Letter4 which includes, as part of the definition of complex products, “other products where complexity or uncertainty concerning the approval pathway or possible alternative approach would benefit from early scientific engagement.”

    Also of note, as part of footnote 8 in the Draft Guidance,3 FDA notes that “meeting requests for products that do not fit within the scope of this guidance will be granted based on the workload and availability of staff and the anticipated value to the ANDA review process.”

    Make sure to note the timetables and plan ahead accordingly. The best outcomes are achieved when the proper footwork is completed up front. We all know the saying, “In God we trust; all others must bring data” (W. Edwards Deming). Providing the proper background information and data is a key aspect of your meeting request and meeting package—and in the case of ANDA meetings, both are submitted at the same time. Generate the data to justify your proposals. This is not the time to throw something out there to see if it sticks; FDA recommends that only one meeting request be submitted per year, per product, so make sure to use it wisely.

    Development Meeting: Common topics for Development meetings are characterization strategies for complex products, as well as Bioequivalence considerations such as alternate approaches or evaluation of study designs. The added benefit of having a Development meeting is that you now also qualify for the mid-cycle review meeting. This is a grand opportunity to vet your development strategy in terms of characterization, QbD, scale-up, design control, etc. No reason not to take advantage and make it count.

    Pre-Submission Meeting: This meeting provides a forum for the Sponsor and FDA to discuss the format and overall content of the ANDA. Although it does not serve as a sneak peek review, it can provide useful information in terms of whether data provided needs clarification, is presented in the proper format or location, or if key content is missing. The challenge here is timing; FDA anticipates holding these meetings six months prior to submission, but as we all know in the world of generics, if your submission is prepared and built—it might be difficult to convince management it is worth the wait.

    Mid-Cycle Review Meeting: A mid-cycle review meeting is not an obligation, but an opportunity to engage with FDA during the review of your ANDA on possible issues that FDA has identified up to that point. This meeting is granted during the ANDA review cycle, especially when a development or a pre-ANDA meeting was held and issues discussed with the Agency. You can accept or decline this opportunity—it is entirely up to you, though I can’t think of a reason why a Sponsor would not relish the chance to receive that coveted, detailed review update.

    Post-Complete Response Meeting: You will not find this meeting type referenced in the Formal Meetings Draft Guidance;3 these meetings enjoy a dedicated Guidance5 all to themselves (FDA Guidance: Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA). The main concepts to remember here are as follows: (1) timing—the request for the meeting must be made within seven days of receipt of the CRL and should be officially submitted to the application, and (2) this meeting is meant to request and receive clarification as to the deficiencies cited in the CRL; it is not a means to receive preliminary review of your response. That being said, we’ve seen some innovative ways of crafting the request for clarification, so that FDA’s responses provide a hint of insight into whether or not your response strategy is sound. 

    So, with the multiple options and many opportunities to engage with FDA, there really is no reason or excuse to sit and wonder if what your development team is proposing for your generic product submission will pass muster with the Agency. Avoid the quandary and just ask! But remember to start early. All these meetings take time and in this competitive world of generics, time or lack of it can be our greatest enemy. 

    References
    1. US Food and Drug Administration.  Center for Drug Evaluation and Research. (2017, November).  Draft Guidance for Industry, Controlled Correspondence Related to Generic Drug Development.  Retrieved from https://www.fda.gov/media/109232/download
    2. Jiang, X.; Navigating Q1/Q2 for Complex Generics; Presented at the Associate of Affordable Medicines GRx+Biosim Conference, Bethesda, MD, November 2019.
    3. US Food and Drug Administration. Center for Drug Evaluation and Research. (2017, October). Draft Guidance for Industry, Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA. Retrieved from https://www.fda.gov/media/107626/download
    4. US Food and Drug Administration. Center for Drug Evaluation and Research. (2016, May). GDUFA II Commitment Letter. Retrieved from https://www.fda.gov/media/101052/download
    5. US Food and Drug Administration.  Center for Drug Evaluation and Research. (2018, December).   Guidance for Industry, Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA.  Retrieved from https://www.fda.gov/media/108337/download


    Michelle Ryder
    Lachman Consultants

    Michelle Ryder is a Principal Consultant in the Regulatory Practice of Lachman Consultants with 20+ years’ experience as a Regulatory professional in the pharmaceutical industry. With her expert knowledge of pharmaceutical regulations, standards, current industry practices, and strong practical experience, she delivers strategic leadership to Lachman’s clients, including for ANDA, NDA, and IND, [505(j), 505(b)(1) and 505(b)(2)] applications as well as throughout the entire project lifecycle.
    Related Searches
    • ndas
    • biosimilar
    • scale-up
    • generic

    Related FDA Watch

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20

    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20


    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20

    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19


    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19

    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19

    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19


    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19

    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19


    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    • Regulatory Affairs
      Elemental Impurity & Risk Assessment

      Elemental Impurity & Risk Assessment

      An update on the retirement of USP General Chapter <231>.
      Paul Mason, Lachman Consultants 07.20.18

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login